Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) operates as an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company maintains its corporate website at www.etonpharma.com.

Eton's commercial portfolio comprises eight rare disease products across endocrinology and metabolic therapeutic areas. The endocrinology segment includes INCRELEX, a biologic treatment for severe primary insulin-like growth factor 1 deficiency approved in 40 territories; ALKINDI SPRINKLE, a granule hydrocortisone formulation for pediatric adrenocortical insufficiency; KHINDIVI, an oral solution hydrocortisone approved in May 2025; and ET-600, a product with a February 2026 FDA PDUFA target action date for diabetes insipidus treatment. The metabolic segment encompasses GALZIN for Wilson disease, PKU GOLIKE for phenylketonuria management, Carglumic Acid for NAGS deficiency, Betaine Anhydrous for homocystinuria, and Nitisinone for tyrosinemia type 1. The company maintains five additional product candidates in late-stage development, including Amglidia for neonatal diabetes mellitus, ET-700 for Wilson disease, ET-800 for adrenal insufficiency, and ZENEO hydrocortisone autoinjector for adrenal crisis.

The company employs 44 full-time employees as of December 31, 2025, with twelve engaged in research and development, twenty-four in sales and marketing operations, and eight in general corporate and strategy roles. Eton commercializes its products through an internal sales force targeting specialty markets and distributes through specialty pharmacies.

Eton's competitive strengths center on business development expertise, regulatory knowledge particularly within the 505(b)(2) pathway, and established commercial infrastructure. The company relies on third-party contract manufacturing organizations based primarily in the United States and Europe for product manufacturing. Eton's intellectual property strategy includes patent protection for key products, with ALKINDI SPRINKLE protected through 2034, KHINDIVI through 2043, and ET-600 through 2044. The company's business model emphasizes identifying and acquiring underappreciated development assets while leveraging existing regulatory data to expedite development timelines and reduce investment requirements.